Page last updated: 2024-08-03 16:54:29

lgk974

Description

LGK974: a potent and specific small-molecule inhibitor of Porcupine (PORCN) acyltransferase [MeSH]

LGK974 : A carboxamide, the structure of which is that of acetamide substituted on carbon by a 2',3-dimethyl-2,4'-bipyridin-5-yl group and on nitrogen by a 5-(pyrazin-2-yl)pyridin-2-yl group. It is a highly potent, selective and orally bioavailable Porcupine inhibitor (a Wnt signalling inhibitor). [CHeBI]

Cross-References

ID Source	ID
PubMed CID	46926973
CHEMBL ID	3188386
SCHEMBL ID	1723611
CHEBI ID	78030
MeSH ID	M0591586

Synonyms (57)

Synonym
NCGC00347950-01
S7143
HY-17545
lgk974
MLS006011002
smr004702800
CHEBI:78030 ,
2-(2',3-dimethyl-2,4'-bipyridin-5-yl)-n-[5-(pyrazin-2-yl)pyridin-2-yl]acetamide
SCHEMBL1723611
2-(2',3-dimethyl-[2,4'-bipyridin]-5-yl)-n-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide
lgk 974
unii-u27f40013q
2-(2',3-dimethyl-(2,4'-bipyridin)-5-yl)-n-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide
U27F40013Q ,
(2,4'-bipyridine)-5-acetamide, 2',3-dimethyl-n-(5-(2-pyrazinyl)-2-pyridinyl)-
wnt-974 [who-dd]
1243244-14-5
lgk-974
wnt-974
wnt974
AC-30231
CHEMBL3188386 ,
AKOS025211913
bdbm50133870
J-005066
mfcd27501026
nvp-lgk974
HMS3653G11
gtpl11167
NCGC00347950-07
2-[5-methyl-6-(2-methyl-4-pyridyl)-3-pyridyl]-n-(5-pyrazin-2-yl-2-pyridyl)acetamide
SW211728-2
DB12561
lgk 974;lgk974; wnt974; wnt 974; wnt-974
BCP08495
Q27147596
lgk974 (wnt974)
EX-A1402
[2,4'-bipyridine]-5-acetamide, 2',3-dimethyl-n-[5-(2-pyrazinyl)-2-pyridinyl]-
SB19314
MS-20504
CCG-264701
CS3177
2-[5-methyl-6-(2-methylpyridin-4-yl)pyridin-3-yl]-n-(5-pyrazin-2-ylpyridin-2-yl)acetamide
NCGC00347950-11
AU-004/43508401
A890524
2-(2',3-dimethyl-[2,4'-bipyridin]-5-yl)-n-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide;lgk974
nsc-777639
nsc777639
NCGC00347950-02
lgk-974 (wnt974)
2-[(2p)-2',3-dimethyl[2,4'-bipyridin]-5-yl]-n-[(5p)-5-(pyrazin-2-yl)pyridin-2-yl]acetamide
o50 ,
porcn inhibitor iv
acotiamide impurity lgk
acotiamide impurity 43

Roles (1)

Role	Description
Wnt signalling inhibitor	A substance that inhibits any of the Wnt signalling pathway, a group of signal transduction pathways made of proteins that pass signals from outside of a cell through cell surface receptors to the inside of the cell.

Drug Classes (4)

Class	Description
bipyridines	Compounds containing a bipyridine group.
pyrazines
pyridines	Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
secondary carboxamide	A carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).

Pathways (4)

lgk974 is involved in 4 pathway(s), involving a total of 1550 unique proteins and 266 unique compounds

Pathway	Proteins	Compounds
Disease	1278	231
Diseases of signal transduction by growth factor receptors and second messengers	262	31
Signaling by WNT in cancer	9	3
LGK974 inhibits PORCN	1	1

Protein Targets (7)

Potency Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	21.3174	AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	19.9242	AID1259252; AID1259253; AID1259255; AID1259256

Inhibition Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
Alpha-2B adrenergic receptor	Rattus norvegicus (Norway rat)	IC50	0.0009	AID1322265
Alpha-2C adrenergic receptor	Rattus norvegicus (Norway rat)	IC50	0.0009	AID1322265
Alpha-2A adrenergic receptor	Rattus norvegicus (Norway rat)	IC50	0.0009	AID1322265
Protein-serine O-palmitoleoyltransferase porcupine	Homo sapiens (human)	IC50	0.0004	AID1257057; AID1457594
Protein-serine O-palmitoleoyltransferase porcupine	Mus musculus (house mouse)	IC50	0.0007	AID1322265; AID1383152; AID1627466

Bioassays (68)

Assay ID	Title	Year	Journal	Article
AID1383152	Inhibition of porcupine in mouse L Wnt3A cells co-cultured with HEK293 cells assessed as suppression of Wnt signaling after 48 hrs by Super-top flash reporter gene assay	2018	European journal of medicinal chemistry, Apr-10, Volume: 149ISSN: 1768-3254	Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID1383193	Effect on Wnt3A levels in HEK293T cells transfected with pLibin-WNT3A plasmid at 100 nM after 48 hrs by Western blot method	2018	European journal of medicinal chemistry, Apr-10, Volume: 149ISSN: 1768-3254	Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID1322265	Inhibition of porcupine in mouse L Wnt3A cells co-cultured with HEK293 cells after 48 hrs by Super-top flash reporter gene assay	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 ISSN: 1464-3391	Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold.
AID1274448	Inhibition of Wnt signaling (unknown origin) expressed in mouse L Wnt3A cells co-cultured with HEK293 cells after 48 hrs by Super-top flash reporter gene assay	2016	European journal of medicinal chemistry, Jan-27, Volume: 108ISSN: 1768-3254	Design, synthesis, and evaluation of potent Wnt signaling inhibitors featuring a fused 3-ring system.
AID1322274	Half life in rat liver microsomes at 1 uM preincubated for 10 mins followed by NADPH addition measured for 30 to 60 mins by LC-MS/MS analysis	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 ISSN: 1464-3391	Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold.
AID1322269	Metabolic stability in rat plasma assessed as remaining compound levels at 1 uM after 8 hrs by LC-MS/MS analysis	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 ISSN: 1464-3391	Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold.
AID1572810	Inhibition of Wnt/beta-catenin pathway in mouse L Wnt3A cells after 48 hrs by TOP-flash dual reporter gene assay	2019	Bioorganic & medicinal chemistry letters, 04-01, Volume: 29, Issue:7 ISSN: 1464-3405	Discovery and structure-activity relationship study of phthalimide-phenylpyridine conjugate as inhibitor of Wnt pathway.
AID1322273	Half life in human liver microsomes at 1 uM preincubated for 10 mins followed by NADPH addition measured for 30 to 60 mins by LC-MS/MS analysis	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 ISSN: 1464-3391	Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold.
AID1383184	Inhibition of porcupine-mediated Wnt/beta-catenin signaling in human PA1 cells assessed as downregulation of disheveled 2 phosphorylation after 48 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Apr-10, Volume: 149ISSN: 1768-3254	Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID1274452	Effect on Wnt3A level in HEK293T cells transfected with pLibin-WNT3A plasmid at 0.1 uM after 48 hrs by Western blot technique	2016	European journal of medicinal chemistry, Jan-27, Volume: 108ISSN: 1768-3254	Design, synthesis, and evaluation of potent Wnt signaling inhibitors featuring a fused 3-ring system.
AID1894735	Inhibition of Wnt signaling pathway in mouse TM3 cells harbouring STF-reporter luciferase gene co-cultured with mouse L Wnt-3A cells incubated for 24 hrs by Bright-Glo Luciferase Assay	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8 ISSN: 1520-4804	Carboxylesterase Notum Is a Druggable Target to Modulate Wnt Signaling.
AID1257057	Inhibition of porcupine activity (unknown origin) expressed in human HT1080 cells assessed as suppression of Wnt3A-mediated super top flash activity by STF luciferase assay	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23 ISSN: 1464-3405	The use of porcupine inhibitors to target Wnt-driven cancers.
AID1322266	Inhibition of porcupine in HEK293T cells transfected with pLibin-WNT3A plasmid assessed as reduction in Wnt3A secretion into cell culture medium at 0.1 uM after 48 hrs by Western blot method	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 ISSN: 1464-3391	Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold.
AID1781278	Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition measured after 72 hrs by MTS assay	2021	Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16 ISSN: 1520-4804
AID1781276	Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay	2021	Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16 ISSN: 1520-4804
AID1383181	Inhibition of porcupine in HEK293 cells transfected with pLibin-WNT3A plasmid assessed as downregulation of disheveled 2 phosphorylation at 100 nM after 48 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Apr-10, Volume: 149ISSN: 1768-3254	Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID1627467	Aqueous solubility of compound in buffer of pH 6.8 after 24 hrs by UV-based high throughput assay	2016	ACS medicinal chemistry letters, Jul-14, Volume: 7, Issue:7 ISSN: 1948-5875	Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors.
AID1383183	Inhibition of porcupine-mediated Wnt/beta-catenin signaling in human PA1 cells assessed as downregulation of Axin2 mRNA expression after 24 hrs by real-time PCR analysis	2018	European journal of medicinal chemistry, Apr-10, Volume: 149ISSN: 1768-3254	Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID1627466	Inhibition of PORCN in mouse Leydig cells overexpressing Wnt3A co-cultured with TM3 cells transfected with Wnt-luciferase gene after 24 hrs by luminescence assay	2016	ACS medicinal chemistry letters, Jul-14, Volume: 7, Issue:7 ISSN: 1948-5875	Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors.
AID1572809	Inhibition of Wnt/beta-catenin pathway in mouse L Wnt3A cells at 10 uM after 48 hrs by TOP-flash dual reporter gene assay relative to control	2019	Bioorganic & medicinal chemistry letters, 04-01, Volume: 29, Issue:7 ISSN: 1464-3405	Discovery and structure-activity relationship study of phthalimide-phenylpyridine conjugate as inhibitor of Wnt pathway.
AID1383180	Inhibition of porcupine in HEK293T cells transfected with pLibin-WNT3A plasmid assessed as reduction in Wnt3A secretion into cell culture medium at 100 nM after 48 hrs by Western blot method	2018	European journal of medicinal chemistry, Apr-10, Volume: 149ISSN: 1768-3254	Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID1781275	Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay	2021	Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16 ISSN: 1520-4804
AID1322275	Half life in mouse liver microsomes at 1 uM preincubated for 10 mins followed by NADPH addition measured for 30 to 60 mins by LC-MS/MS analysis	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 ISSN: 1464-3391	Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold.
AID1383186	Inhibition of smo-mediated hedgehog signaling pathway in mouse NIH3T3 cells expressing GRE-Luc reporter gene assessed as inhibition of SAG-induced GRE-Luc reporter activity after 48 hrs by luminescence assay	2018	European journal of medicinal chemistry, Apr-10, Volume: 149ISSN: 1768-3254	Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID1457594	Inhibition of porcupine (unknown origin)	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15 ISSN: 1520-4804	Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors.
AID1781274	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay	2021	Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16 ISSN: 1520-4804
AID1383185	Inhibition of porcupine-mediated Wnt/beta-catenin signaling in human PA1 cells assessed as downregulation of LRP6 phosphorylation after 48 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Apr-10, Volume: 149ISSN: 1768-3254	Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID1322270	Intrinsic clearance in human liver microsomes at 1 uM preincubated for 10 mins followed by NADPH addition measured for 30 to 60 mins by LC-MS/MS analysis	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 ISSN: 1464-3391	Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold.
AID1322267	Effect on Wnt3A level in HEK293T cells transfected with pLibin-WNT3A plasmid at 0.1 uM after 48 hrs by Western blot method	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 ISSN: 1464-3391	Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold.
AID1274451	Inhibition of porcupine (unknown origin) in HEK293T cells transfected with pLibin-WNT3A plasmid assessed as reduction in Wnt3A secretion into cell culture medium at 0.1 uM after 48 hrs by Western blot technique	2016	European journal of medicinal chemistry, Jan-27, Volume: 108ISSN: 1768-3254	Design, synthesis, and evaluation of potent Wnt signaling inhibitors featuring a fused 3-ring system.
AID1322271	Intrinsic clearance in rat liver microsomes at 1 uM preincubated for 10 mins followed by NADPH addition measured for 30 to 60 mins by LC-MS/MS analysis	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 ISSN: 1464-3391	Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold.
AID1383182	Inhibition of porcupine in HEK293 cells transfected with pLibin-WNT3A plasmid assessed as downregulation of LRP6 phosphorylation at 100 nM after 48 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Apr-10, Volume: 149ISSN: 1768-3254	Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID1322268	Chemical stability in simulated gastric fluid assessed as remaining compound levels at 200 uM at 40 degC after 24 hrs by HPLC method	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 ISSN: 1464-3391	Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold.
AID1383192	Inhibition of smo-mediated hedgehog signaling pathway in mouse NIH3T3-Luc cells assessed as downregulation of Gli mRNA expression at 1 uM after 48 hrs by real-time PCR analysis	2018	European journal of medicinal chemistry, Apr-10, Volume: 149ISSN: 1768-3254	Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
AID1781277	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay	2021	Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16 ISSN: 1520-4804
AID1322272	Intrinsic clearance in mouse liver microsomes at 1 uM preincubated for 10 mins followed by NADPH addition measured for 30 to 60 mins by LC-MS/MS analysis	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 ISSN: 1464-3391	Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 ISSN: 2472-5560	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4 ISSN: 2211-1247	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173ISSN: 1872-9096	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845	Primary qHTS for Inhibitors of ATXN expression	2022	The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4 ISSN: 1949-2553	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7 ISSN: 1554-8937	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.

Research

Studies (54)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	32 (59.26)	24.3611
2020's	22 (40.74)	2.80

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (3.70%)	5.53%
Reviews	3 (5.56%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	49 (90.74%)	84.16%

Substance	Classes	Roles	Relationship Strength
abt 702	bipyridines		low
amrinone	bipyridines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor	low
milrinone	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent	low
olprinone	bipyridines		low
anatabine	bipyridines		low
benzyl viologen	bipyridines		low
5,5'-dimethyl-2,2'-bipyridyl	bipyridines		low
anabaseine	bipyridines		low
orellanine	bipyridines		low
mk 0663	bipyridines; organochlorine compound; sulfone	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug	low
anabasamine	bipyridines		low
2-amino-4-pyridin-4-yl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-3-carbonitrile	bipyridines		low
2-amino-4-(2-furanyl)-6-(2-pyridinyl)-3-pyridinecarbonitrile	bipyridines		low
2-(3-carboxy-2-pyridinyl)-3-pyridinecarboxylic acid	bipyridines		low
4-pyridin-4-yl-2-sulfanylidene-5,6,7,8-tetrahydro-1H-quinoline-3-carbonitrile	bipyridines		low
LSM-16285	bipyridines		low
2-[(3,4-dichlorophenyl)methylthio]-6-(3-pyridinyl)-3-pyridinecarbonitrile	bipyridines		low
4-[[3-cyano-4-methyl-6-(3-pyridinyl)-2-pyridinyl]thio]-3-oxobutanoic acid ethyl ester	bipyridines		low
2-amino-4-(2-fluorophenyl)-6-(3-pyridinyl)-3-pyridinecarbonitrile	bipyridines		low
2-amino-6-methyl-4-(3-pyridinyl)-5,6,7,8-tetrahydroquinoline-3-carbonitrile	bipyridines		low
perampanel	bipyridines; nitrile; pyridone	AMPA receptor antagonist; anticonvulsant	low
cerulomycin	aldoxime; aromatic ether; bipyridines; pyridine alkaloid	antineoplastic agent; bacterial metabolite; marine metabolite	low
pyrazinamide	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug	low
5-(n,n-hexamethylene)amiloride	aromatic amine; azepanes; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines	antineoplastic agent; apoptosis inducer; odorant receptor antagonist; sodium channel blocker	low
ethylisopropylamiloride	aromatic amine; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines; tertiary amino compound	anti-arrhythmia drug; neuroprotective agent; sodium channel blocker	low
glipizide	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue	low
sulfalene	pyrazines; sulfonamide antibiotic; sulfonamide		low
pyrazines	diazine; pyrazines	Daphnia magna metabolite	low
aspergillic acid	pyrazines		low
tetramethylpyrazine	alkaloid; pyrazines	antineoplastic agent; apoptosis inhibitor; bacterial metabolite; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent	low
amiloride	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker	low
2,3-Dimethylpyrazine	pyrazines		low
2-ethyl-3,5-dimethylpyrazine	pyrazines		low
2,3,5-trimethylpyrazine	pyrazines	animal metabolite; bacterial metabolite; flavouring agent; pheromone; plant metabolite	low
2,3-Diethyl-5-methylpyrazine	pyrazines		low
2,5-dimethylpyrazine	pyrazines		low
oltipraz	1,2-dithiole; pyrazines	angiogenesis modulating agent; antimutagen; antineoplastic agent; antioxidant; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; neurotoxin; protective agent; schistosomicide drug	low
morphazinamide	morpholines; pyrazines; secondary carboxamide		low
methyl 3-aminopyrazine-2-carboxylate	aromatic amine; methyl ester; pyrazines		low
cyanopyrazine	nitrile; pyrazines		low
2-chloropyrazine	pyrazines		low
2-aminopyrazine	pyrazines		low
benzamil	guanidines; pyrazines		low
3',4'-dichlorobenzamil	guanidines; pyrazines		low
5-hydroxypyrazinamide	carboxamide; pyrazines		low
6-chloro-3,5-diaminopyrazine-3-carboxamide	organochlorine compound; pyrazines		low
2,3-diphenylpyrazine	pyrazines		low
bortezomib	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor	low
isradipine	pyrazines	oxidized luciferins	low
2-methoxy-N-methyl-N-[5-(5-methyl-2-pyrazinyl)-1,3,4-thiadiazol-2-yl]acetamide	pyrazines		low
N-methyl-N-[5-(5-methyl-2-pyrazinyl)-1,3,4-thiadiazol-2-yl]-2-oxolanecarboxamide	pyrazines		low
N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-pyrazinecarboxamide	primary carboxamide; pyrazines; secondary carboxamide		low
N'-[1-oxo-2-(4-propan-2-ylphenoxy)ethyl]-2-pyrazinecarbohydrazide	carbohydrazide; pyrazines		low
N'-[2-(4-bromo-2-methylphenoxy)-1-oxoethyl]-2-pyrazinecarbohydrazide	carbohydrazide; pyrazines		low
N-[1-[(4-chlorophenyl)methyl]-4-pyrazolyl]-2-pyrazinecarboxamide	pyrazines; secondary carboxamide		low
2,6-bis(1-pyrazolyl)pyrazine	pyrazines		low
n-(4-(n-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide	pyrazines; sulfonamide; thiophenes	necroptosis inhibitor; neuroprotective agent	low
N-[5-[(2,6-dichlorophenyl)methylthio]-1,3,4-thiadiazol-2-yl]-5-methyl-2-pyrazinecarboxamide	pyrazines; secondary carboxamide		low
yoda 1	aromatic compound; dichlorobenzene; organic sulfide; pyrazines; thiadiazoles	glycine transporter 2 inhibitor; piezo1 agonist	low
3,5-Dimethylpyrazin-2-amine	pyrazines		low
telaprevir	cyclopentapyrrole; cyclopropanes; oligopeptide; pyrazines	antiviral drug; hepatitis C protease inhibitor; peptidomimetic	low
selexipag	aromatic amine; ether; monocarboxylic acid amide; N-sulfonylcarboxamide; pyrazines; tertiary amino compound	orphan drug; platelet aggregation inhibitor; prodrug; prostacyclin receptor agonist; vasodilator agent	low
mre 269	aromatic amine; ether; monocarboxylic acid; pyrazines; sulfonamide; tertiary amino compound	drug metabolite; orphan drug; platelet aggregation inhibitor; prostacyclin receptor agonist; vasodilator agent	low
azd2858	aromatic amine; N-methylpiperazine; pyrazines; pyridines; secondary carboxamide; sulfonamide	antineoplastic agent; bone density conservation agent; EC 2.7.11.26 (tau-protein kinase) inhibitor; Wnt signalling activator	low
cx 5461	diazepine; naphthyridine derivative; organic heterotetracyclic compound; pyrazines; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.7.6 (RNA polymerase) inhibitor	low
gilteritinib	aromatic amine; monomethoxybenzene; N-methylpiperazine; oxanes; piperidines; primary carboxamide; pyrazines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
3-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]-6-(phenylmethylene)piperazine-2,5-dione	pyrazines		low
phenylamil	guanidines; pyrazines		low
3-cyanopyridine	nitrile; pyridines		low
2-(3-pyridine)acetic acid	monocarboxylic acid; pyridines	human xenobiotic metabolite	low
nicotine 1-n-oxide	pyridines; pyrrolidine N-oxides		low
norcotinine	pyridines; pyrrolidines		low
4-oxo-4-(3-pyridyl)butanoic acid	aromatic ketone; monocarboxylic acid; pyridines		low
pyridine	azaarene; mancude organic heteromonocyclic parent; monocyclic heteroarene; pyridines	environmental contaminant; NMR chemical shift reference compound	low
carbinoxamine	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist	low
chlorpheniramine	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor	low
disopyramide	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug	low
doxylamine	pyridines; tertiary amine	anti-allergic agent; antiemetic; antitussive; cholinergic antagonist; H1-receptor antagonist; histamine antagonist; sedative	low
fusaric acid	aromatic carboxylic acid; pyridines		low
iproniazid	carbohydrazide; pyridines		low
lansoprazole	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor	low
entinostat	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	low
niflumic acid	aromatic carboxylic acid; pyridines		low
omeprazole	aromatic ether; benzimidazoles; pyridines; sulfoxide		low
pantoprazole	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic	low
pheniramine	pyridines; tertiary amino compound		low
pinacidil	pyridines		low
pioglitazone	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic	low
pirbuterol	pyridines		low
pyridinolcarbamate	pyridines		low
quipazine	piperazines; pyridines		low
rabeprazole	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor	low
sb 202190	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
risedronic acid	pyridines		low
imatinib	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor	low
streptonigrin	pyridines; quinolone	antimicrobial agent; antineoplastic agent	low
sulfapyridine	pyridines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; dermatologic drug; drug allergen; environmental contaminant; xenobiotic	low
tazarotene	acetylenic compound; ethyl ester; pyridines; retinoid; thiochromane	keratolytic drug; prodrug; teratogenic agent	low
n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine	N-substituted diamine; pyridines; tertiary amino compound	apoptosis inducer; chelator; copper chelator	low
thurfyl nicotinate	aromatic carboxylic acid; pyridines		low
brompheniramine	organobromine compound; pyridines	anti-allergic agent; H1-receptor antagonist	low
methyl nicotinate	aromatic carboxylic acid; pyridines		low
citrazinic acid	aromatic carboxylic acid; pyridines		low
nicotinyl alcohol	aromatic primary alcohol; pyridines	antilipemic drug; vasodilator agent	low
beta-nicotyrine	pyridines		low
3-ethylpyridine	pyridines		low
2-Pyridinylmethanol	pyridines		low
nicoboxil	aromatic carboxylic acid; pyridines		low
clopyralid	organochlorine pesticide; pyridines	herbicide	low
oxiniacic acid	aromatic carboxylic acid; pyridines		low
2-(aminomethyl)pyridine	pyridines		low
propiram	pyridines		low
n'-nitrosonornicotine	pyridines; pyrrolidines		low
[4-(2-pyridinyl)-1-piperazinyl]-(3,4,5-trimethoxyphenyl)methanone	piperazines; pyridines		low
5-hydroxynicotinic acid	aromatic carboxylic acid; pyridines		low
n-cyano-n'-(1,1-dimethylpropyl)-n''-(3-pyridinyl)guanidine	pyridines		low
4-(n-methyl-n-nitrosamino)-1-(3-pyridyl)-1-butanone	nitrosamine; pyridines		low
haloxyfop	aromatic ether; monocarboxylic acid; organochlorine compound; organofluorine compound; pyridines		low
fluazifop-butyl	aromatic ether; carboxylic ester; organofluorine compound; pyridines		low
imazapyr, (+-)-isomer	imidazolines; imidazolone; pyridinemonocarboxylic acid; pyridines		low
imazethapyr	aromatic carboxylic acid; pyridines		low
2,2'-dipyridyl disulfide	organic disulfide; pyridines	oxidising agent	low
droxicam	organic heterotricyclic compound; pyridines	cyclooxygenase 1 inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor; prodrug	low
methyridine	pyridines		low
picosulfate sodium	aryl sulfate; pyridines		low
2-hydroxynicotinic acid	aromatic carboxylic acid; pyridines		low
ethylnicotinate	aromatic carboxylic acid; pyridines		low
nicametate	aromatic carboxylic acid; pyridines		low
nicotinamide n-oxide	pyridines		low
nicosulfuron	N-sulfonylurea; pyridines; pyrimidines	environmental contaminant; herbicide; xenobiotic	low
4,4'-dipyridyl disulfide	organic disulfide; pyridines		low
2-Chloronicotinic acid	aromatic carboxylic acid; pyridines		low
4-methoxymethylpyridoxine	pyridines		low
6-chloronicotinic acid	aromatic carboxylic acid; pyridines		low
2-pyridylacetic acid	pyridines		low
fluazifop	aromatic ether; monocarboxylic acid; organofluorine compound; pyridines		low
pyriproxyfen	aromatic ether; pyridines	juvenile hormone mimic	low
dithiopyr	organofluorine compound; pyridines; thioester		low
thiazopyr	aromatic carboxylic acid; pyridines		low
dpx e9636	aromatic ether; N-sulfonylurea; pyridines; pyrimidines; sulfone	environmental contaminant; herbicide; xenobiotic	low
clodinafop-propargyl	aromatic ether; carboxylic ester; organochlorine compound; organofluorine compound; propyzamide; pyridines	agrochemical; EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor; herbicide	low
flazasulfuron	pyridines; sulfonamide		low
2,6-dichloroisonicotinic acid	monocarboxylic acid; organochlorine compound; pyridines	EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor	low
difenpiramide	biphenyls; monocarboxylic acid amide; pyridines	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug	low
4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol	nitrosamine; pyridines; secondary alcohol	biomarker; carcinogenic agent; human urinary metabolite	low
hydroxycotinine	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid		low
5-hydroxymethylomeprazole	aromatic ether; benzimidazoles; pyridines; sulfoxide	drug metabolite	low
forasartan	benzenes; pyridines; tetrazoles; triazoles	angiotensin receptor antagonist; antihypertensive agent	low
abiraterone	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; pyridines	antineoplastic agent; EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor	low
agn 190299	monocarboxylic acid; pyridines; retinoid; thiochromane	keratolytic drug; teratogenic agent	low
vatalanib	monochlorobenzenes; phthalazines; pyridines; secondary amino compound	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist	low
metyrapol	pyridines		low
sb 203580	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent	low
aminopyralid	aromatic amine; organochlorine pesticide; pyridines	herbicide	low
dabigatran etexilate	aromatic amide; benzimidazoles; beta-alanine derivative; carboxamidine; carboxylic ester; pyridines	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; prodrug	low
dabigatran	aromatic amide; benzimidazoles; beta-alanine derivative; carboxamidine; pyridines	anticoagulant; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; EC 3.4.21.5 (thrombin) inhibitor	low
alpha-(trichloromethyl)-4-pyridineethanol	pyridines		low
6-methyl-2-oxo-4-(trifluoromethyl)-1H-pyridine-3-carbonitrile	nitrile; pyridines		low
gant58	pyridines		low
3-(3-pyridinyl)propanoic acid	pyridines		low
rosoxacin	pyridines; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; antiinfective agent	low
gant 61	aminal; dialkylarylamine; pyridines; substituted aniline; tertiary amino compound	antineoplastic agent; apoptosis inducer; glioma-associated oncogene inhibitor; Hedgehog signaling pathway inhibitor	low
e 3040	benzothiazoles; organic hydroxy compound; pyridines; secondary amino compound	anti-inflammatory drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; uricosuric drug	low
E3040 glucuronide	benzothiazoles; beta-D-glucosiduronic acid; pyridines; secondary amino compound	xenobiotic metabolite	low
cerivastatin	dihydroxy monocarboxylic acid; pyridines; statin (synthetic)		low
hts 466284	pyrazoles; pyridines; quinolines	TGFbeta receptor antagonist	low
prinomastat	aromatic ether; hydroxamic acid; pyridines; sulfonamide; thiomorpholines	antineoplastic agent; EC 3.4.24.35 (gelatinase B) inhibitor; matrix metalloproteinase inhibitor	low
6-methyl-2-oxo-5-[oxo-(1-phenylethylamino)methyl]-1H-pyridine-3-carboxylic acid ethyl ester	aromatic carboxylic acid; pyridines		low
5-(2-furanyl)-3-(3-pyridinyl)-1,2,4-oxadiazole	pyridines		low
1-(2-pyridin-4-yl-1-oxa-3,4-diazaspiro[4.6]undec-2-en-4-yl)ethanone	pyridines		low
s 1033	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor	low
2-pyridinecarboxylic acid [2-(2,3-dichloroanilino)-2-oxoethyl] ester	aromatic carboxylic acid; pyridines		low
N-methyl-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)-3-oxolanecarboxamide	pyridines		low
5-(4-propylcyclohexyl)-3-(3-pyridinyl)-1,2,4-oxadiazole	pyridines		low
N-methyl-N-[5-(2-pyridinyl)-1,3,4-thiadiazol-2-yl]-3-oxolanecarboxamide	pyridines		low
2-methoxy-N-methyl-N-[5-(2-pyridinyl)-1,3,4-thiadiazol-2-yl]acetamide	pyridines		low
6-methyl-2-[4-[oxo(thiophen-2-yl)methyl]-1-piperazinyl]-3-quinolinecarbonitrile	piperazines; pyridines		low
[5-(2-furanyl)-7-(trifluoromethyl)-2-pyrazolo[1,5-a]pyrimidinyl]-[4-(2-pyridinyl)-1-piperazinyl]methanone	piperazines; pyridines		low
6-hydroxy-1-(3-hydroxypropyl)-4-methyl-2-oxo-5-(1-piperidinylmethyl)-3-pyridinecarbonitrile	nitrile; pyridines		low
5,8-dimethoxy-4-(4-methyl-1-piperazinyl)-2-(trifluoromethyl)quinoline	piperazines; pyridines		low
5-ethyl-4,6-dimethyl-2-sulfanylidene-1H-pyridine-3-carbonitrile	nitrile; pyridines		low
8-(2-furanyl)-6-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]-3,3-dimethyl-1,4-dihydrothiopyrano[3,4-c]pyridine-5-carbonitrile	piperazines; pyridines		low
N-(4-{[2-(pyridin-3-yl)piperidin-1-yl]sulfonyl}phenyl)acetamide	acetamides; piperidines; pyridines; sulfonamide		low
2-(pyridin-4-yl)-4-(pyrrolidin-1-yl)quinazoline	pyridines; pyrrolidines; quinazolines		low
2-methyl-3-phenyl-5-propyl-7-[4-(2-pyridinyl)-1-piperazinyl]pyrazolo[1,5-a]pyrimidine	piperazines; pyridines		low
prothionamide	pyridines		low
N2-(4-fluorophenyl)-6-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-1,3,5-triazine-2,4-diamine	piperazines; pyridines		low
1-(4-methyl-1,2,5-oxadiazol-3-yl)-3-(3-pyridinyl)urea	pyridines		low
N-(3-fluorophenyl)-2-(pyridin-4-yl)quinazolin-4-amine	aromatic amine; monofluorobenzenes; pyridines; quinazolines; secondary amino compound; substituted aniline		low
5-cyano-2-methyl-6-sulfanylidene-1H-pyridine-3-carboxylic acid ethyl ester	aromatic carboxylic acid; pyridines		low
2-(1H-imidazol-1-yl)-5-(trifluoromethyl)pyridine	pyridines		low
5-(3-pyridinylmethyl)-1,3,5-triazinane-2-thione	pyridines		low
2-amino-5-ethyl-4-(2-furanyl)-6-propyl-3-pyridinecarbonitrile	nitrile; pyridines		low
4-(methoxymethyl)-6-methyl-2-(2-methylanilino)-3-pyridinecarbonitrile	nitrile; pyridines		low
GS4012 free base	aryl sulfide; monomethoxybenzene; pyridines	VEGF activator	low
5-(phenylmethyl)-3-(2-pyridinyl)-1,2,4-oxadiazole	pyridines		low
4-(methoxymethyl)-6-methyl-2-(4-phenyl-1-piperazinyl)-3-pyridinecarbonitrile	piperazines; pyridines		low
1-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-2-benzo[cd]indolone	piperazines; pyridines		low
cotinine	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid	antidepressant; biomarker; human xenobiotic metabolite; plant metabolite	low
1-propylsulfonyl-4-(2-pyridinyl)piperazine	piperazines; pyridines		low
2-(2-phenylethylthio)-3-pyridinecarboxylic acid	aromatic carboxylic acid; pyridines		low
1,3-benzothiazol-2-yl-[4-(2-pyridinyl)-1-piperazinyl]methanone	piperazines; pyridines		low
2-(2,6-dichloroanilino)-3-pyridinesulfonamide	pyridines; sulfonamide		low
4-(4-chloroanilino)-3-pyridinesulfonamide	pyridines; sulfonamide		low
6-(2-oxopropylthio)-3-pyridinecarboxylic acid	aromatic carboxylic acid; pyridines		low
6-chloro-N-(2-hydroxyphenyl)-3-pyridinesulfonamide	pyridines; sulfonamide		low
3-(phenylmethyl)-6-pyridin-4-yl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole	pyridines; triazolothiadiazole		low
6-(4-benzoyl-1-piperazinyl)-3,3-dimethyl-8-propan-2-yl-1,4-dihydropyrano[3,4-c]pyridine-5-carbonitrile	piperazines; pyridines		low
5-bromo-6-chloro-N-(4-methyl-2-pyridinyl)-3-pyridinesulfonamide	pyridines; sulfonamide		low
pyrabactin	naphthalenes; organobromine compound; pyridines; sulfonamide	abscisic acid receptor agonist; hormone; plant growth regulator	low
4-[4-(benzenesulfonyl)-1-piperazinyl]-2-methylquinoline	piperazines; pyridines		low
2-(4-bromophenyl)-1-[4-(2-pyridinyl)-1-piperazinyl]ethanone	piperazines; pyridines		low
(4-chlorophenyl)-[4-(7-chloro-4-quinolinyl)-1-piperazinyl]methanone	piperazines; pyridines		low
7-chloro-4-[4-(3,4-dimethylphenyl)sulfonyl-1-piperazinyl]quinoline	piperazines; pyridines		low
1-ethyl-3-sulfanylidene-5,6,7,8-tetrahydro-2H-isoquinoline-4-carbonitrile	pyridines		low
7-methoxy-2-[4-[(2-methylphenyl)-oxomethyl]-1-piperazinyl]-3-quinolinecarbonitrile	piperazines; pyridines		low
6-tert-butyl-2-oxo-4-(trifluoromethyl)-1H-pyridine-3-carbonitrile	nitrile; pyridines		low
5-cyano-2-phenyl-6-[4-(2-pyridinyl)-1-piperazinyl]-3-pyridinecarboxylic acid ethyl ester	piperazines; pyridines		low
N,N-dibutyl-2-(pyridin-4-yl)quinazolin-4-amine	pyridines; quinazolines; tertiary amino compound		low
4,6-dimethyl-2-[3-(4-morpholinyl)propylamino]-3-pyridinecarbonitrile	nitrile; pyridines		low
2-ethoxy-3-pyridinecarboxylic acid [2-[1-(2-furanylmethyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl] ester	aromatic carboxylic acid; pyridines		low
mcb-613	cyclic ketone; enone; pyridines	antineoplastic agent; steroid receptor coactivator stimulator	low
5,6-dichloro-3-pyridinecarboxylic acid [2-(2-furanylmethylamino)-2-oxoethyl] ester	aromatic carboxylic acid; pyridines		low
4-pyridinecarboxylic acid [2-[1-(2-furanylmethyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl] ester	aromatic carboxylic acid; pyridines		low
2-oxo-1H-pyridine-3-carboxylic acid [2-(2,5-dimethyl-1-propyl-3-pyrrolyl)-2-oxoethyl] ester	aromatic carboxylic acid; pyridines		low
2-thiopyridine	aryl thiol; pyridines	allergen; fluorescence quencher	low
2-(methylamino)-6-thiophen-2-yl-4-(trifluoromethyl)-3-pyridinecarbonitrile	nitrile; pyridines		low
2-(1-piperidinyl)-6-thiophen-2-yl-4-(trifluoromethyl)-3-pyridinecarbonitrile	nitrile; pyridines		low
N-benzyl-N'-methyl-N-(pyridin-3-ylmethyl)thiourea	pyridines		low
3-Chloro-5-(trifluoromethyl)pyridine-2-carbothioamide	pyridines		low
2,6-dimethyl-4-(3-thienyl)pyridine-3,5-dicarboxylic acid	aromatic carboxylic acid; pyridines		low
N-tert-butyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarboxamide	piperazines; pyridines		low
5-cyano-2-(methoxymethyl)-6-sulfanylidene-1H-pyridine-3-carboxylic acid methyl ester	aromatic carboxylic acid; pyridines		low
ethionamide	pyridines; thiocarboxamide	antilipemic drug; antitubercular agent; fatty acid synthesis inhibitor; leprostatic drug; prodrug	low
2-amino-6-[4-(6-chloro-2-pyridinyl)-1-piperazinyl]pyridine-3,5-dicarbonitrile	piperazines; pyridines		low
2-(propylthio)nicotinic acid	aromatic carboxylic acid; pyridines		low
5-Chloro-2-hydroxy-4,6-dimethylnicotinonitrile	nitrile; pyridines		low
3-[1-(2,4-dichlorophenyl)sulfonyl-2-pyrrolidinyl]pyridine	pyridines; pyrrolidines		low
(3,5-dichlorophenyl)-[4-[2-(trifluoromethyl)-4-quinolinyl]-1-piperazinyl]methanone	piperazines; pyridines		low
3-[5-[[4-(2-pyridinyl)-1-piperazinyl]sulfonyl]-2-thiophenyl]isoxazole	piperazines; pyridines		low
2-oxo-4,6-dithiophen-2-yl-1H-pyridine-3-carbonitrile	nitrile; pyridines		low
4-[4-(3-bromophenyl)sulfonyl-1-piperazinyl]-7-chloroquinoline	piperazines; pyridines		low
3,7-dimethyl-2-[4-(2-pyridinyl)-1-piperazinyl]quinoline	piperazines; pyridines		low
3-phenyl-1-[4-(2-pyridinyl)-1-piperazinyl]-1-propanone	piperazines; pyridines		low
4-phenoxy-1-[4-(2-pyridinyl)-1-piperazinyl]-1-butanone	piperazines; pyridines		low
2-[4-(2-methyl-4-quinolinyl)-1-piperazinyl]-4-phenylthiazole	piperazines; pyridines		low
6-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)-N-ethyl-N-phenyl-3-pyridinesulfonamide	pyridines; sulfonamide		low
alpha-nicotyrine	pyridines		low
dapiprazole	N-alkylpiperazine; N-arylpiperazine; pyridines	alpha-adrenergic antagonist; antipsychotic agent; miotic; ophthalmology drug	low
glucitol hexanicotinate	aromatic carboxylic acid; pyridines		low
6,8-difluoro-4-(pyridin-3-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline	organic heterotricyclic compound; organofluorine compound; pyridines; secondary amino compound		low
N-(1,3-benzodioxol-5-ylmethyl)-N-[2-(cyclohexylamino)-2-oxo-1-pyridin-4-ylethyl]-2,2,2-trifluoroacetamide	benzodioxoles; pyridines; secondary carboxamide; tertiary carboxamide; trifluoroacetamide		low
1-methyl-4-[[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]thio]-2-quinolinone	piperazines; pyridines		low
1-(4-amino-1,2,5-oxadiazol-3-yl)-5-[(2-pyridinylthio)methyl]-4-triazolecarboxylic acid propan-2-yl ester	aryl sulfide; azole; isopropyl ester; oxadiazole; pyridines		low
6-bromo-3-[4-oxo-4-[4-(2-pyridinyl)-1-piperazinyl]butyl]-2-sulfanylidene-1H-quinazolin-4-one	piperazines; pyridines		low
N-[4-methyl-2-(4-methyl-1-piperazinyl)-6-quinolinyl]-1,3-benzodioxole-5-carboxamide	piperazines; pyridines		low
4-[2-(1-cyclohexenyl)ethyl]-1-cyclohexyl-3-pyridin-4-ylpiperazine-2,5-dione	piperazines; pyridines		low
ml012	piperazines; pyridines		low
[4-(2-pyrimidinyl)-1-piperazinyl]-[1-[4-(2-pyrimidinyl)-1-piperazinyl]-4-isoquinolinyl]methanone	piperazines; pyridines		low
N-(2-furanylmethyl)-N'-[4-methyl-2-(4-methyl-1-piperazinyl)-6-quinolinyl]butanediamide	piperazines; pyridines		low
[3-(4-methylphenyl)-1-phenyl-4-pyrazolyl]-[4-(2-pyridinyl)-1-piperazinyl]methanone	piperazines; pyridines		low
2-pyridinecarboxylic acid [2-(5-chloro-2-thiophenyl)-2-oxoethyl] ester	aromatic carboxylic acid; pyridines		low
2-[[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]thio]-3-pyridinecarboxylic acid [2-[(2-methoxyphenyl)methylamino]-2-oxoethyl] ester	aromatic carboxylic acid; pyridines		low
2-[(5-formyl-2-methoxyphenyl)methylthio]-3-pyridinecarboxylic acid	aromatic carboxylic acid; pyridines		low
[3-(2,3-dihydroindol-1-ylsulfonyl)phenyl]-[4-(2-pyridinyl)-1-piperazinyl]methanone	piperazines; pyridines		low
3-(4-benzoyl-1-piperazinyl)-1-(2-methylpropyl)-6,7-dihydro-5H-cyclopenta[c]pyridine-4-carbonitrile	piperazines; pyridines		low
5-cyano-6-[4-(4-methoxyphenyl)-1-piperazinyl]-2-oxo-1H-pyridine-3-carboxylic acid ethyl ester	piperazines; pyridines		low
2-[4-(3-chlorophenyl)-1-piperazinyl]-3-pyridinecarboxylic acid propan-2-yl ester	isopropyl ester; piperazines; pyridines		low
3-(1-hydroxy-5,5-dimethyl-4-phenyl-2H-imidazol-2-yl)pyridine	pyridines		low
[4-[(2-chlorophenyl)methylsulfonyl]-3-nitrophenyl]-[4-(2-pyridinyl)-1-piperazinyl]methanone	piperazines; pyridines		low
2-pyridinecarboxylic acid [2-[2-(difluoromethoxy)anilino]-2-oxoethyl] ester	aromatic carboxylic acid; pyridines		low
hydroxypioglitazone	aromatic ether; pyridines; thiazolidinediones	human xenobiotic metabolite	low
2-(2-fluoroanilino)-3-pyridinecarboxylic acid [2-[(1,1-dioxo-3-thiolanyl)-methylamino]-2-oxoethyl] ester	aromatic carboxylic acid; pyridines		low
3-(4-ethylphenyl)-4-hydroxy-4-[oxo-[4-(2-pyridinyl)-1-piperazinyl]methyl]-1H-quinazolin-2-one	piperazines; pyridines		low
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amine	aromatic amine; piperidines; pyridines; quinazolines; secondary amino compound; tertiary amino compound		low
abt724	piperazines; pyridines		low
2-(4-acetyl-1-piperazinyl)-6-amino-4-(cyanomethyl)pyridine-3,5-dicarbonitrile	piperazines; pyridines		low
triprolidine	N-alkylpyrrolidine; olefinic compound; pyridines	H1-receptor antagonist	low
pibutidine	aromatic ether; cyclobutenones; olefinic compound; piperidines; primary amino compound; pyridines; secondary amino compound	anti-ulcer drug; H2-receptor antagonist	low
acrivastine	alpha,beta-unsaturated monocarboxylic acid; N-alkylpyrrolidine; olefinic compound; pyridines	H1-receptor antagonist	low
2-[3-(diethylamino)propylamino]-4-(methoxymethyl)-6-methyl-3-pyridinecarbonitrile	nitrile; pyridines		low
[2-(1-piperidinyl)-1,3-benzothiazol-6-yl]-[4-(2-pyridinyl)-1-piperazinyl]methanone	piperazines; pyridines		low
N-[2-(4-ethyl-1-piperazinyl)-4-methyl-6-quinolinyl]-2-pyrazinecarboxamide	piperazines; pyridines		low
clodinafop	aromatic ether; monocarboxylic acid; organochlorine compound; organofluorine compound; pyridines	EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor; phenoxy herbicide	low
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one	enone; pyridines	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.1.105 (6-phosphofructo-2-kinase) inhibitor	low
[4-(3-chlorophenyl)sulfonyl-3-nitrophenyl]-[4-(2-pyridinyl)-1-piperazinyl]methanone	piperazines; pyridines		low
axitinib	aryl sulfide; benzamides; indazoles; pyridines	antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist	low
2-[4-(2-pyrimidinyl)-1-piperazinyl]quinoline	piperazines; pyridines		low
(2-Chloro-4-pyridinyl)methanol	organohalogen compound; pyridines		low
pymetrozine	1,2,4-triazines; pyridines	antifeedant; environmental contaminant; TRPV channel modulator; xenobiotic	low
abiraterone acetate	pyridines; sterol ester	antineoplastic agent; EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor; prodrug	low
mocetinostat	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent	low
n-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2h)-carboxamide	piperazines; pyridines		low
4-(1H-imidazol-5-ylmethyl)pyridine	pyridines		low
680c91	fluoroindole; olefinic compound; pyridines	EC 1.13.11.11 (tryptophan 2,3-dioxygenase) inhibitor	low
masitinib	1,3-thiazoles; benzamides; N-alkylpiperazine; pyridines	antineoplastic agent; antirheumatic drug; tyrosine kinase inhibitor	low
vorapaxar	carbamate ester; lactone; naphthofuran; organofluorine compound; pyridines	cardiovascular drug; platelet aggregation inhibitor; protease-activated receptor-1 antagonist	low
ciclonicate	aromatic carboxylic acid; pyridines		low
tedizolid	carbamate ester; organofluorine compound; oxazolidinone; primary alcohol; pyridines; tetrazoles	antimicrobial agent; drug metabolite; protein synthesis inhibitor	low
chlorantranilipole	monochlorobenzenes; organobromine compound; pyrazole insecticide; pyrazoles; pyridines; secondary carboxamide	ryanodine receptor agonist	low
picoxystrobin	aromatic ether; enoate ester; enol ether; methoxyacrylate strobilurin antifungal agent; organofluorine compound; pyridines	antifungal agrochemical; mitochondrial cytochrome-bc1 complex inhibitor	low
tedizolid phosphate	carbamate ester; organofluorine compound; oxazolidinone; phosphate monoester; pyridines; tetrazoles	antimicrobial agent; prodrug; protein synthesis inhibitor	low
dorsomorphin	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor	low
cyantraniliprole	nitrile; organobromine compound; organochlorine compound; pyrazole insecticide; pyridines; secondary carboxamide	ryanodine receptor agonist	low
GDC-0879	indanes; ketoxime; primary alcohol; pyrazoles; pyridines	antineoplastic agent; B-Raf inhibitor	low
bgt226	aromatic ether; imidazoquinoline; N-arylpiperazine; organofluorine compound; pyridines	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor	low
[4-(3-chlorophenyl)-1-piperazinyl]-[1-[4-(2-pyridinyl)-1-piperazinyl]-4-isoquinolinyl]methanone	piperazines; pyridines		low
dafadine C	aromatic amide; aromatic ether; difluorobenzene; isoxazoles; N-acylpiperidine; pyridines	P450 inhibitor	low
dafadine B	aromatic amide; aromatic ether; isoxazoles; monochlorobenzenes; monofluorobenzenes; N-acylpiperidine; pyridines	P450 inhibitor	low
1-butyl-3-[2-(4-ethyl-1-piperazinyl)-4-methyl-6-quinolinyl]-1-methylthiourea	piperazines; pyridines		low
lumacaftor	aromatic amide; benzodioxoles; benzoic acids; cyclopropanes; organofluorine compound; pyridines	CFTR potentiator; orphan drug	low
ro5126766	aryloxypyrimidine; coumarins; organofluorine compound; pyridines; sulfamides	antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
sulfoxaflor	nitrile; organofluorine compound; pyridines; sulfoximide		low
cnf 2024	2-aminopurines; aromatic ether; organochlorine compound; pyridines	antineoplastic agent; Hsp90 inhibitor	low
gdc 0449	benzamides; monochlorobenzenes; pyridines; sulfone	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent	low
bms 754807	pyrazoles; pyridines; pyrrolidines; pyrrolotriazine	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
4-(1-((5-((2,6-dimethylphenoxy)methyl)-3-isoxazolyl)carbonyl)-4-piperidinyl)pyridine	aromatic amide; aromatic ether; isoxazoles; N-acylpiperidine; pyridines	geroprotector; P450 inhibitor	low
dafadine D	aromatic amide; aromatic ether; isoxazoles; N-acylpiperidine; organofluorine compound; pyridines	P450 inhibitor	low
dafadine O	aromatic amide; aromatic ether; isoxazoles; N-acylpiperidine; pyridines; ring assembly	P450 inhibitor	low
florbetapir f 18	(18)F radiopharmaceutical; aromatic ether; organofluorine compound; pyridines; substituted aniline	radioactive imaging agent	low
sch772984	biaryl; indazoles; N-acylpiperazine; N-alkylpyrrolidine; N-arylpiperazine; pyridines; pyrimidines; pyrrolidinecarboxamide; secondary carboxamide; tertiary amino compound; tertiary carboxamide	analgesic; antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
gsk 2126458	aromatic ether; difluorobenzene; pyridazines; pyridines; quinolines; sulfonamide	anticoronaviral agent; antineoplastic agent; autophagy inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor; radiosensitizing agent	low
1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-(2-pyridinylsulfonyl)piperazine	pyridines; sulfonamide		low
ml228 probe	1,2,4-triazines; biphenyls; pyridines; secondary amino compound	hypoxia-inducible factor pathway activator	low
N-(4,6-dimethyl-2-pyridinyl)-4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarbothioamide	piperazines; pyridines		low
afidopyropen	cyclopropanecarboxylate ester; organic heterotetracyclic compound; pyridines; secondary alcohol	agrochemical; insecticide; TRPV channel modulator	low
piroxicam	benzothiazine; monocarboxylic acid amide; pyridines	analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug	low
mobiflex	heteroaryl hydroxy compound; monocarboxylic acid amide; pyridines; thienothiazine	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug	low
lornoxicam	heteroaryl hydroxy compound; monocarboxylic acid amide; organochlorine compound; pyridines; thienothiazine	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug	low
MK-8353	aromatic ether; dihydropyridine; indazoles; methyl sulfide; N-alkylpyrrolidine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; triazoles	antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
gsk-2816126	piperazines; pyridines		low
acp-196	aromatic amine; benzamides; imidazopyrazine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; ynone	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor	low
GSK1059615	pyridines; quinolines; thiazolidinone	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor	low
pf-06687252	azabicycloalkane; enone; phenols; pyridines		low
2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrile	hydroxyindoles; morpholines; nitrile; pyridines; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; tau aggregation inhibitor	low
sb-590885	aromatic ether; imidazoles; ketoxime; pyridines; tertiary amino compound		low
dabigatran etexilate	aromatic amide; benzimidazoles; beta-alanine derivative; carboxamidine; carboxylic ester; pyridines	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; prodrug	low
butoctamide succinate	dicarboxylic acid monoester; hemisuccinate; secondary carboxamide		low
cl 387785	bromobenzenes; quinazolines; secondary carboxamide; ynamide	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist	low
iodipamide	benzoic acids; organoiodine compound; secondary carboxamide	radioopaque medium	low
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide	benzamides; hydroxamic acid; secondary carboxamide; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	low
nemonapride	benzamides; monochlorobenzenes; monomethoxybenzene; N-alkylpyrrolidine; secondary amino compound; secondary carboxamide; substituted aniline		low
niclosamide	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor	low
pd168393	acrylamides; bromobenzenes; quinazolines; secondary carboxamide; substituted aniline	epidermal growth factor receptor antagonist	low
pilsicainide	organic heterobicyclic compound; secondary carboxamide	anti-arrhythmia drug; sodium channel blocker	low
pj-34	phenanthridines; secondary carboxamide; tertiary amino compound	angiogenesis inhibitor; anti-inflammatory agent; antiatherosclerotic agent; antineoplastic agent; apoptosis inducer; cardioprotective agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; neuroprotective agent	low
opc 12759	secondary carboxamide		low
suramin	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug	low
2-[[3-(3,4-dimethoxyphenyl)-1-oxoprop-2-enyl]amino]benzoic acid	amidobenzoic acid; cinnamamides; secondary carboxamide		low
acedapsone	acetamides; anilide; secondary carboxamide; sulfone	antimalarial; antimicrobial drug	low
salicylurate	N-acylglycine; secondary carboxamide	human xenobiotic metabolite; uremic toxin	low
monoacetyldapsone	acetamides; anilide; secondary carboxamide; sulfone		low
n-methylolacrylamide	secondary carboxamide		low
win 18446	organochlorine compound; secondary carboxamide	EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor	low
carboxin	anilide fungicide; anilide; enamide; organosulfur heterocyclic compound; oxacycle; secondary carboxamide	antifungal agrochemical; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor	low
tromantadine	secondary carboxamide		low
aureothricin	dithiolopyrrolone antibiotic; secondary carboxamide	angiogenesis inhibitor; antibacterial agent; bacterial metabolite; EC 2.7.7.6 (RNA polymerase) inhibitor	low
amperozide	diarylmethane; monofluorobenzenes; N-alkylpiperazine; secondary carboxamide; ureas	anxiolytic drug; dopamine uptake inhibitor; geroprotector; second generation antipsychotic; serotonergic antagonist	low
n-acetyltryptophanamide	acetamides; L-tryptophan derivative; primary carboxamide; secondary carboxamide		low
gamma-glutamyltyrosine	dicarboxylic acid; dipeptide; phenols; primary amino compound; secondary carboxamide	human metabolite	low
n-acetyldopamine	acetamides; catechols; N-(fatty acyl)-dopamine; secondary carboxamide	human urinary metabolite; marine metabolite	low
n-acetylcytidine	acetamides; cytidines; secondary carboxamide	metabolite	low
florfenicol	organochlorine compound; organofluorine compound; secondary alcohol; secondary carboxamide; sulfone	antimicrobial agent	low
marimastat	hydroxamic acid; secondary carboxamide	antineoplastic agent; matrix metalloproteinase inhibitor	low
n-(3-oxohexanoyl)-3-aminodihydro-2(3h)-furanone	N-acyl homoserine lactone; secondary carboxamide		low
mosapride	aromatic ether; benzamides; monochlorobenzenes; monofluorobenzenes; morpholines; secondary carboxamide; substituted aniline; tertiary amino compound		low
benzyloxycarbonylphenylalanylphenylalanine diazomethyl ketone	carboxylic ester; diazo compound; L-phenylalanine derivative; secondary carboxamide	cathepsin L (EC 3.4.22.15) inhibitor	low
yh 439	aromatic amide; isopropyl ester; secondary carboxamide		low
cyc 682	nitrile; nucleoside analogue; secondary carboxamide	antimetabolite; antineoplastic agent; DNA synthesis inhibitor; prodrug	low
sceptrin	pyrroles; secondary carboxamide		low
n(beta)-alanyldopamine	catechols; primary amino compound; secondary carboxamide		low
monoacetylcadaverine	acetamides; N-substituted cadaverine; primary amino compound; secondary carboxamide	human metabolite	low
N-(1-phenylethyl)acetamide	acetamides; secondary carboxamide		low
2,2,2-trifluoro-N-[2-(1H-indol-3-yl)ethyl]acetamide	indoles; secondary carboxamide; trifluoroacetamide		low
xv 638	1,3-thiazoles; benzamides; diazepanone; diol; secondary alcohol; secondary carboxamide; ureas	HIV protease inhibitor	low
vibriobactin	1,3-oxazoles; secondary carboxamide	siderophore	low
bms 195614	benzoic acids; quinolines; secondary carboxamide	retinoic acid receptor alpha antagonist	low
tempace	aminoxyls; piperidinecarboxamide; secondary carboxamide	radiation protective agent; radical scavenger	low
dimethyloxalylglycine	glycine derivative; methyl ester; secondary carboxamide	EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor; neuroprotective agent	low
3-methyl-2-[[oxo-(4-pentoxyphenyl)methyl]amino]butanoic acid	secondary carboxamide		low
cinromide	cinnamamides; secondary carboxamide		low
4-[[2-furanyl(oxo)methyl]amino]benzoic acid propan-2-yl ester	aromatic amide; furans; isopropyl ester; secondary carboxamide		low
2,2,2-trifluoro-N-(2-methyl-8-quinolinyl)acetamide	quinolines; secondary carboxamide; trifluoroacetamide		low
2-[[oxo(thiophen-2-yl)methyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid propan-2-yl ester	aromatic amide; isopropyl ester; secondary carboxamide; thiophenes		low
4-[[(4-bromo-2-ethyl-3-pyrazolyl)-oxomethyl]amino]benzoic acid propan-2-yl ester	aromatic amide; isopropyl ester; secondary carboxamide		low
(2S)-2-[[(2-chlorophenyl)-oxomethyl]amino]-3-methylbutanoic acid (6-nitro-4H-1,3-benzodioxin-8-yl)methyl ester	secondary carboxamide		low
N-[(2S)-1-(1H-benzimidazol-2-ylamino)-3-methyl-1-oxobutan-2-yl]-3,5-dimethoxybenzamide	secondary carboxamide		low
2-(2,4-dioxo-1H-pyrimidin-6-yl)-N-[2-(4-morpholinyl)ethyl]acetamide	morpholines; pyrimidone; secondary carboxamide; tertiary amino compound		low
N-[(4-chlorophenyl)methyl]-2-(2,4-dioxo-1H-pyrimidin-6-yl)acetamide	monochlorobenzenes; pyrimidone; secondary carboxamide		low
N-[(2S)-1-(1H-benzimidazol-2-ylamino)-3-methyl-1-oxobutan-2-yl]-3-methylbenzamide	secondary carboxamide		low
2,2,2-trifluoro-N-(5-oxo-1-phenyl-4H-pyrazol-3-yl)acetamide	pyrazoles; secondary carboxamide; trifluoroacetamide		low
N-(2-anilino-2-oxoethyl)-2-methoxybenzamide	secondary carboxamide		low
(2S)-3-methyl-2-[[(3-methylphenyl)-oxomethyl]amino]butanoic acid (4-oxo-2-pyrimido[2,1-b][1,3]benzothiazolyl)methyl ester	secondary carboxamide		low
n-(1-oxyl-2,2,6,6-tetramethyl-4-piperidinyl)iodoacetamide	aminoxyls; organoiodine compound; piperidinecarboxamide; secondary carboxamide	radical scavenger; spin label	low
ANA-12	1-benzothiophenes; caprolactams; secondary carboxamide	antidepressant; anxiolytic drug; tropomyosin-related kinase B receptor antagonist	low
N-([biphenyl]-2-yl)-3-cyclopentylpropanamide	biphenyls; cyclopentanes; secondary carboxamide		low
bms 387032	1,3-oxazoles; 1,3-thiazoles; organic sulfide; piperidinecarboxamide; secondary carboxamide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	low
sr 144528	bridged compound; monochlorobenzenes; pyrazoles; secondary carboxamide	CB2 receptor antagonist; EC 2.3.1.26 (sterol O-acyltransferase) inhibitor	low
N-[2-(cyclohexylamino)-2-oxo-1-thiophen-2-ylethyl]-2,2,2-trifluoro-N-(4-methylphenyl)acetamide	secondary carboxamide; tertiary carboxamide; thiophenes; trifluoroacetamide		low
ML162	monochlorobenzenes; monomethoxybenzene; organochlorine compound; secondary carboxamide; tertiary carboxamide; thiophenes	EC 1.11.1.9 (glutathione peroxidase) inhibitor; ferroptosis inducer	low
N-[3-(N-(2-chloro-1-oxoethyl)-4-nitroanilino)propyl]-2,2,2-trifluoroacetamide	C-nitro compound; secondary carboxamide; tertiary carboxamide; trifluoroacetamide		low
2-[[2-(3,4-dimethoxyanilino)-2-oxoethyl]thio]-3-pyridinecarboxylic acid propan-2-yl ester	dimethoxybenzene; isopropyl ester; secondary carboxamide		low
fagaramide	cinnamamides; secondary carboxamide		low
arachidonyl dopamine	catechols; fatty amide; N-(fatty acyl)-dopamine; secondary carboxamide		low
n-oleoyldopamine	catechols; fatty amide; N-(fatty acyl)-dopamine; secondary carboxamide	TRPV1 agonist	low
tranilast	amidobenzoic acid; cinnamamides; dimethoxybenzene; secondary carboxamide	anti-allergic agent; anti-asthmatic drug; antineoplastic agent; aryl hydrocarbon receptor agonist; calcium channel blocker; hepatoprotective agent; nephroprotective agent	low
arachidonyl-2-chloroethylamide	fatty amide; organochlorine compound; secondary carboxamide; synthetic cannabinoid	CB1 receptor agonist; CB2 receptor agonist; neuroprotective agent	low
l796778	benzenes; C-nitro compound; L-lysine derivative; L-phenylalanine derivative; methyl ester; oligopeptide; secondary carboxamide; ureas	somatostatin receptor agonist	low
l803087	benzenes; fluoroindole; guanidines; L-arginine derivative; methyl ester; phenylindole; secondary carboxamide	somatostatin receptor agonist	low
n-cinnamoyltyramine	cinnamamides; phenols; secondary carboxamide	allelochemical; antimicrobial agent; phytoalexin; platelet aggregation inhibitor	low
ag-490	catechols; enamide; monocarboxylic acid amide; nitrile; secondary carboxamide	anti-inflammatory agent; antioxidant; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector; STAT3 inhibitor	low
4-amylcinnamoylanthranilic acid	amidobenzoic acid; cinnamamides; secondary carboxamide	EC 3.1.1.4 (phospholipase A2) inhibitor; TRP channel blocker	low
batimastat	hydroxamic acid; L-phenylalanine derivative; organic sulfide; secondary carboxamide; thiophenes; triamide	angiogenesis inhibitor; antineoplastic agent; matrix metalloproteinase inhibitor	low
pipercallosidine	alkaloid; benzodioxoles; enamide; secondary carboxamide	apoptosis inducer; metabolite; plant metabolite	low
pederin	cyclic ketal; diol; oxanes; polyketide; secondary alcohol; secondary carboxamide	antimitotic; antineoplastic agent; bacterial metabolite; vesicant	low
streptogramin a	1,3-oxazoles; cyclic ketone; enamide; lactam; macrolide antibiotic; macrolide; pyrroline; secondary alcohol; secondary carboxamide; tertiary carboxamide	antibacterial drug; Mycoplasma genitalium metabolite	low
cinanserin	aryl sulfide; cinnamamides; secondary carboxamide; tertiary amino compound	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor	low
pepstatin	pentapeptide; secondary carboxamide	bacterial metabolite; EC 3.4.23.* (aspartic endopeptidase) inhibitor	low
ximelagatran	amidoxime; azetidines; carboxamide; ethyl ester; hydroxylamines; secondary amino compound; secondary carboxamide; tertiary carboxamide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; prodrug; serine protease inhibitor	low
(6R,7R)-7-[[(2R)-2-carboxy-2-(4-hydroxyphenyl)-1-oxoethyl]amino]-7-methoxy-3-[[(1-methyl-5-tetrazolyl)thio]methyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid	dicarboxylic acid; secondary carboxamide		low
salubrinal	aminal; organochlorine compound; quinolines; secondary carboxamide; thioureas		low
DPI2	benzenes; morpholines; secondary carboxamide; tertiary amino compound; thiazolidinone	ferroptosis inducer	low
su 1498	enamide; monocarboxylic acid amide; nitrile; phenols; secondary carboxamide	vascular endothelial growth factor receptor antagonist	low
n-feruloylserotonin	aromatic ether; cinnamamides; hydroxyindoles; phenols; secondary carboxamide	plant metabolite	low
oroidin	pyrroles; secondary carboxamide	metabolite	low
ro 42-5892	cyclopropanes; diol; L-histidine derivative; secondary carboxamide; sulfone	antihypertensive agent; EC 3.4.23.15 (renin) inhibitor; peptidomimetic; vasodilator agent	low
s 1006	1,3-thiazoles; carbamate ester; carboxylic acid; cephalosporin; enamide; secondary carboxamide	antibacterial drug	low
manumycin	enamide; epoxide; organic heterobicyclic compound; polyketide; secondary carboxamide; tertiary alcohol	antiatherosclerotic agent; antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; marine metabolite	low
asukamycin	enamide; epoxide; organic heterobicyclic compound; polyketide; secondary carboxamide; tertiary alcohol	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; bacterial metabolite	low
kalimantacin a	alpha,beta-unsaturated monocarboxylic acid; carbamate ester; fatty acid derivative; secondary carboxamide	antibacterial agent; antimicrobial agent; bacterial metabolite	low
l 744832	benzenes; ether; isopropyl ester; secondary carboxamide; sulfone; thiol	antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; geroprotector	low
l 779976	benzimidazoles; indoles; piperidinecarboxamide; primary amino compound; secondary carboxamide	neuroprotective agent; somatostatin receptor agonist	low
ustiloxin b	aromatic ether; heterodetic cyclic peptide; macrocycle; phenols; secondary alcohol; secondary carboxamide; sulfoxide	Aspergillus metabolite; microtubule-destabilising agent; mycotoxin	low
dysidenin	1,3-thiazoles; organochlorine compound; secondary carboxamide; tertiary carboxamide	animal metabolite; marine metabolite; toxin	low
avenanthramide b	amidobenzoic acid; cinnamamides; monohydroxybenzoic acid; monomethoxybenzene; phenols; secondary carboxamide	antineoplastic agent; apoptosis inducer; phytoalexin	low
bibw 2992	aromatic ether; enamide; furans; monochlorobenzenes; organofluorine compound; quinazolines; secondary carboxamide; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor	low
betrixaban	benzamides; guanidines; monochloropyridine; monomethoxybenzene; secondary carboxamide	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor	low
fr 900848	cyclopropanes; nucleoside analogue; olefinic compound; polyketide; secondary carboxamide	antifungal agent; bacterial metabolite	low
pha 665752	dichlorobenzene; enamide; indolones; N-acylpyrrolidine; pyrrolecarboxamide; secondary carboxamide; sulfone; tertiary carboxamide	antineoplastic agent; c-Met tyrosine kinase inhibitor	low
n-benzylhexadecanamide	macamide; secondary carboxamide	EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor; neuroprotective agent; plant metabolite	low
cenicriviroc	aromatic ether; benzazocine; diether; imidazoles; secondary carboxamide; sulfoxide	anti-HIV agent; anti-inflammatory agent; antirheumatic drug; chemokine receptor 2 antagonist; chemokine receptor 5 antagonist	low
at 7519	dichlorobenzene; piperidines; pyrazoles; secondary carboxamide	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	low
azd 1152	anilide; monoalkyl phosphate; monofluorobenzenes; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor; prodrug	low
pf 00299804	enamide; monochlorobenzenes; monofluorobenzenes; piperidines; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist	low
MI-63	azaspiro compound; monochlorobenzenes; monofluorobenzenes; morpholines; oxindoles; pyrrolidines; secondary carboxamide	apoptosis inducer	low
PF-00835231	aromatic ether; indolecarboxamide; L-leucine derivative; primary alcohol; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; drug metabolite; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor	low
VPC 23019	aromatic amide; D-serine derivative; organic phosphate; phosphoric ester; secondary carboxamide	sphingosine-1-phosphate receptor 1 antagonist; sphingosine-1-phosphate receptor 3 antagonist	low
pd 0348292	monochlorobenzenes; monofluorobenzenes; pyridone; pyrrolidines; secondary carboxamide; ureas	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor; serine protease inhibitor	low
narlaprevir	azabicyclohexane; cyclopropanes; pyrrolidinecarboxamide; secondary carboxamide; sulfone; tertiary carboxamide; ureas	anticoronaviral agent; antiviral drug; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; hepatitis C protease inhibitor	low
tosedostat	carboxylic ester; hydroxamic acid; secondary carboxamide		low
4-chloro-N-[1-[[5-(ethylthio)-1,3,4-thiadiazol-2-yl]amino]-3-methyl-1-oxobutan-2-yl]benzamide	secondary carboxamide		low
azd 1152-hqpa	anilide; monofluorobenzenes; primary alcohol; pyrazoles; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; Aurora kinase inhibitor	low
CDN1163	aromatic ether; quinolines; secondary carboxamide	SERCA activator	low
(2S)-2-[[[5-[[5-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]pentylamino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]propanoic acid tert-butyl ester	secondary carboxamide; tert-butyl ester		low
(2S)-2-[[[5-[[methyl-(phenylmethyl)amino]-oxomethyl]-1H-imidazol-4-yl]-oxomethyl]amino]-6-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]hexanoic acid tert-butyl ester	secondary carboxamide; tert-butyl ester; tertiary carboxamide		low
(2S,3S,4R)-4-cyclopropyl-2-ethoxy-3-(3-hydroxypropyl)-N-prop-2-ynyl-3,4-dihydro-2H-pyran-6-carboxamide	secondary carboxamide		low
sid 26681509	carbohydrazide; L-tryptophan derivative; secondary carboxamide; tert-butyl ester; thioester	antiplasmodial drug; cathepsin L (EC 3.4.22.15) inhibitor	low
azd 7545	benzamides; monochlorobenzenes; organofluorine compound; secondary carboxamide; sulfone; tertiary alcohol; tertiary carboxamide	EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor; hypoglycemic agent	low
sm 164	benzenes; organic heterobicyclic compound; secondary carboxamide; triazoles	antineoplastic agent; apoptosis inducer; radiosensitizing agent	low
GRL-0617	benzamides; naphthalenes; secondary carboxamide; substituted aniline	anticoronaviral agent; protease inhibitor	low
entrectinib	benzamides; difluorobenzene; indazoles; N-methylpiperazine; oxanes; secondary amino compound; secondary carboxamide	antibacterial agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
TAK-580	1,3-thiazolecarboxamide; aminopyrimidine; chloropyridine; organofluorine compound; pyrimidinecarboxamide; secondary carboxamide	antineoplastic agent; apoptosis inducer; B-Raf inhibitor	low
KOM70144	acetamides; benzamides; naphthalenes; secondary carboxamide	anticoronaviral agent; protease inhibitor	low
monepantel	(trifluoromethyl)benzenes; aromatic ether; aryl sulfide; nitrile; secondary carboxamide	anthelminthic drug; nematicide	low
ulixacaltamide	benzamides; monochlorobenzenes; monofluorobenzenes; piperidines; secondary carboxamide	non-narcotic analgesic; T-type calcium channel blocker	low
EG00229	benzothiadiazole; dicarboxylic acid monoamide; L-arginine derivative; secondary carboxamide; sulfonamide; thiophenes	angiogenesis inhibitor; antineoplastic agent; neuropilin receptor antagonist	low
tak-632	(trifluoromethyl)benzenes; aromatic ether; benzothiazoles; cyclopropylcarboxamide; monofluorobenzenes; nitrile; secondary carboxamide	antineoplastic agent; apoptosis inducer; B-Raf inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; necroptosis inhibitor	low
gsk-5498a	(trifluoromethyl)benzenes; difluorobenzene; pyrazoles; secondary carboxamide	calcium channel blocker	low
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide	aromatic ether; methylpyridines; olefinic compound; quinazolines; secondary amino compound; secondary carboxamide; toluenes		low
raltegravir	1,2,4-oxadiazole; dicarboxylic acid amide; hydroxypyrimidine; monofluorobenzenes; pyrimidone; secondary carboxamide	antiviral drug; HIV-1 integrase inhibitor	low
lfm a13	aromatic amide; dibromobenzene; enamide; enol; nitrile; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 2.7.11.21 (polo kinase) inhibitor; geroprotector; platelet aggregation inhibitor	low
teriflunomide	(trifluoromethyl)benzenes; aromatic amide; enamide; enol; nitrile; secondary carboxamide	drug metabolite; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; hepatotoxic agent; non-steroidal anti-inflammatory drug; tyrosine kinase inhibitor	low
gsk1265744	difluorobenzene; monocarboxylic acid amide; organic heterotricyclic compound; secondary carboxamide	HIV-1 integrase inhibitor	low
dolutegravir	difluorobenzene; monocarboxylic acid amide; organic heterotricyclic compound; secondary carboxamide	HIV-1 integrase inhibitor	low
LimKi 3	1,3-thiazoles; dichlorobenzene; organofluorine compound; pyrazoles; secondary carboxamide	LIM kinase inhibitor	low
gsk343	aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor	low
osimertinib	acrylamides; aminopyrimidine; biaryl; indoles; monomethoxybenzene; secondary amino compound; secondary carboxamide; substituted aniline; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist	low
ivosidenib	cyanopyridine; monochlorobenzenes; organofluorine compound; pyrrolidin-2-ones; secondary carboxamide; tertiary carboxamide	antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor	low
atogepant	azaspiro compound; organic heterotetracyclic compound; piperidones; secondary carboxamide; trifluorobenzene	calcitonin gene-related peptide receptor antagonist	low
DDR1-IN-1	(trifluoromethyl)benzenes; aromatic ether; benzamides; N-alkylpiperazine; oxindoles; secondary carboxamide	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
bictegravir	monocarboxylic acid amide; organic heterotetracyclic compound; secondary carboxamide; trifluorobenzene	HIV-1 integrase inhibitor	low
THZ531	aminopyrimidine; enamide; indoles; N-acylpiperidine; organochlorine compound; secondary amino compound; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor	low
AZ3451	benzimidazoles; benzodioxoles; nitrile; organobromine compound; secondary carboxamide	anti-inflammatory agent; autophagy inducer; PAR2 negative allosteric modulator	low
MMP-9-IN-1	aromatic compound; organic sulfide; organofluorine compound; pyrimidone; secondary carboxamide	antineoplastic agent; EC 3.4.24.35 (gelatinase B) inhibitor	low
althiomycin	1,3-thiazoles; aldoxime; ether; gamma-lactam; pentapeptide; peptide antibiotic; primary alcohol; pyrroline; secondary carboxamide; tertiary carboxamide	antibacterial agent; bacterial metabolite; protein synthesis inhibitor	low
colibactin	1,3-thiazoles; azaspiro compound; polyketide; pyrroline; secondary carboxamide	alkylating agent; carcinogenic agent; Escherichia coli metabolite; genotoxin	low
N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide	aldehyde; indolecarboxamide; oligopeptide; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor	low
3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide	aldehyde; indolecarboxamide; monofluorobenzenes; oligopeptide; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor	low
PF-07304814	aromatic ether; indolecarboxamide; L-leucine derivative; phosphate monoester; pyrrolidin-2-ones; secondary carboxamide	anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; prodrug	low
nirmatrelvir	azabicyclohexane; nitrile; organofluorine compound; pyrrolidin-2-ones; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide	anticoronaviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor	low

Substance	Classes	Roles	Relationship Strength
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid	chromanol; monocarboxylic acid; phenols	antioxidant; ferroptosis inhibitor; neuroprotective agent; radical scavenger; Wnt signalling inhibitor	low
toxoflavin	carbonyl compound; pyrimidotriazine	antibacterial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; toxin; virulence factor; Wnt signalling inhibitor	low
6-cyclohexyl-3-furan-2-yl-(1,2,4)triazolo(3,4-b)(1,3,4)thiadiazole	furans; triazolothiadiazole	Wnt signalling inhibitor	low
iwr-1 endo	benzamides; bridged compound; dicarboximide; quinolines	axin stabilizer; Wnt signalling inhibitor	low
CCT251545	azaspiro compound; chloropyridine; pyrazoles	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; Wnt signalling inhibitor	low

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	2010's	post-2020
melatonin	1	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger	2021	2021	3.0	low	0	1
n-acetylserotonin	1	acetamides; N-acylserotonin; phenols	antioxidant; human metabolite; mouse metabolite; tropomyosin-related kinase B receptor agonist	2021	2021	3.0	low	0	1
theophylline	1	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent	2021	2021	3.0	low	0	1
caffeine	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic	2021	2021	3.0	low	0	1
icg 001	1	peptide		2021	2021	3.0	low	0	1
gdc 0449	1	benzamides; monochlorobenzenes; pyridines; sulfone	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent	2018	2018	6.0	low	1	0
iwr-1 endo	1	benzamides; bridged compound; dicarboximide; quinolines	axin stabilizer; Wnt signalling inhibitor	2021	2021	3.0	low	0	1
wnt-c59	1			2015	2015	9.0	low	1	0

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	Trials	2010's	post-2020
dimethyl sulfoxide	1	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger	2020	2020	4.0	low	0	1	0
aspirin	1	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent	2020	2020	4.0	low	0	1	0
celecoxib	1	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2015	2015	9.0	low	0	1	0
fluorouracil	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic	2019	2019	5.0	low	0	1	0
temozolomide	1	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug	2015	2015	9.0	low	0	1	0
serine	1	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2022	2022	2.0	low	0	0	1
histidine	1	amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite	2022	2022	2.0	low	0	0	1
quinazolines	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines		2020	2020	4.0	low	0	1	0
indazoles	1	indazole		2015	2015	9.0	low	0	1	0
pyrazines	37	diazine; pyrazines	Daphnia magna metabolite	2013	2022	5.5	high	1	28	9
paraquat	1	organic cation	geroprotector; herbicide	2018	2018	6.0	low	0	1	0
camptothecin	1	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite	2015	2015	9.0	low	0	1	0
paclitaxel	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent	2019	2019	5.0	low	0	1	0
irinotecan	1	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug	2015	2015	9.0	low	0	1	0
triazoles	1	1,2,3-triazole		2015	2015	9.0	low	0	1	0
coenzyme a	1	adenosine 3',5'-bisphosphate	coenzyme; Escherichia coli metabolite; mouse metabolite	2022	2022	2.0	low	0	0	1
artesunic acid	1			2022	2022	2.0	low	0	0	1
methotrexate	1	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent	2021	2021	3.0	low	0	0	1
nsc 668036	2			2019	2019	5.0	high	0	2	0
puromycin	1	puromycins	antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor	2020	2020	4.0	low	0	1	0
palmitoyl coenzyme a	1	11,12-saturated fatty acyl-CoA; 3-substituted propionyl-CoA; long-chain fatty acyl-CoA; palmitoyl bioconjugate	Escherichia coli metabolite; mouse metabolite	2022	2022	2.0	low	0	0	1
salinomycin	1	polyketide; spiroketal	animal growth promotant; potassium ionophore	2015	2015	9.0	low	0	1	0
encorafenib	1			2023	2023	1.0	low	1	0	1
wnt-c59	1			2015	2015	9.0	low	0	1	0
g007-lk	1			2015	2015	9.0	low	0	1	0
icg 001	2			2019	2021	4.0	low	0	1	1
dacarbazine	1	dacarbazine		2015	2015	9.0	low	0	1	0
xav939	2	(trifluoromethyl)benzenes; thiopyranopyrimidine	tankyrase inhibitor	2015	2018	7.5	low	0	2	0
pyrimidinones	2			2019	2021	4.0	low	0	1	1

Condition	Indicated	Studies	First Year	Last Year	Average Age	Relationship Strength	Trials	2010's	post-2020
Abnormalities, Autosome	0	1	2017	2017	7.0	low	0	1	0
Adenocarcinoma Of Kidney	0	1	2020	2020	4.0	low	0	1	0
Adenocarcinoma of Lung	0	1	2018	2018	6.0	low	0	1	0
Adenoma	0	1	2018	2018	6.0	low	0	1	0
Adenoma, Basal Cell	0	1	2018	2018	6.0	low	0	1	0
ADPKD	0	1	2018	2018	6.0	low	0	1	0
Alloxan Diabetes	0	1	2019	2019	5.0	low	0	1	0
Arachnoidal Cerebellar Sarcoma, Circumscribed	0	1	2015	2015	9.0	low	0	1	0
Astrocytoma, Grade IV	0	1	2015	2015	9.0	low	0	1	0
Asymmetric Diabetic Proximal Motor Neuropathy	0	1	2019	2019	5.0	low	0	1	0
Atrial Remodeling	0	1	2017	2017	7.0	low	0	1	0
Benign Neoplasms	0	8	2013	2022	5.6	low	1	4	4
Benign Neoplasms, Brain	0	2	2015	2015	9.0	low	0	2	0
Blood Poisoning	0	1	2021	2021	3.0	low	0	0	1
Brain Neoplasms	0	2	2015	2015	9.0	low	0	2	0
Breast Cancer	0	1	2019	2019	5.0	low	0	1	0
Breast Neoplasms	0	1	2019	2019	5.0	low	0	1	0
Cancer of Colon	0	1	2017	2017	7.0	low	0	1	0
Cancer of Head	0	1	2021	2021	3.0	low	0	0	1
Cancer of Kidney	0	1	2020	2020	4.0	low	0	1	0
Cancer of Liver	0	1	2017	2017	7.0	low	0	1	0
Cancer of Lung	0	1	2018	2018	6.0	low	0	1	0
Cancer of Prostate	0	1	2016	2016	8.0	low	0	1	0
Cancer of Skin	0	1	2018	2018	6.0	low	0	1	0
Cancer of Testis	0	1	2021	2021	3.0	low	0	0	1
Cancer of the Tongue	0	1	2021	2021	3.0	low	0	0	1
Cancer, Embryonal	0	1	2021	2021	3.0	low	0	0	1
Carcinogenesis	0	1	2018	2018	6.0	low	0	1	0
Carcinoma, Epidermoid	0	1	2018	2018	6.0	low	0	1	0
Carcinoma, Renal Cell	0	1	2020	2020	4.0	low	0	1	0
Carcinoma, Squamous Cell	1	1	2018	2018	6.0	low	0	1	0
Carcinoma, Squamous Cell of Head and Neck	0	1	2021	2021	3.0	low	0	0	1
Cardiovascular Stroke	0	1	2017	2017	7.0	low	0	1	0
Cell Transformation, Neoplastic	0	1	2018	2018	6.0	low	0	1	0
Colonic Neoplasms	0	1	2017	2017	7.0	low	0	1	0
Colorectal Cancer	0	6	2015	2023	5.3	low	1	5	1
Colorectal Neoplasms	0	6	2015	2023	5.3	low	1	5	1
Congenital Zika Syndrome	0	1	2020	2020	4.0	low	0	1	0
Diabetic Neuropathies	0	1	2019	2019	5.0	low	0	1	0
Disease Models, Animal	0	2	2018	2020	5.0	low	0	2	0
Endotoxemia	0	1	2021	2021	3.0	low	0	0	1
ER-Negative PR-Negative HER2-Negative Breast Cancer	0	1	2015	2015	9.0	low	0	1	0
Genetic Predisposition	0	1	2020	2020	4.0	low	0	1	0
Germinoblastoma	0	1	2020	2020	4.0	low	0	1	0
Glial Cell Tumors	0	1	2015	2015	9.0	low	0	1	0
Glioblastoma	0	1	2015	2015	9.0	low	0	1	0
Glioma	0	1	2015	2015	9.0	low	0	1	0
Head and Neck Neoplasms	0	1	2021	2021	3.0	low	0	0	1
HPV Infection	0	1	2018	2018	6.0	low	0	1	0
Hypercalcemia	0	1	2023	2023	1.0	low	1	0	1
Idiopathic Parkinson Disease	0	1	2018	2018	6.0	low	0	1	0
Inflammation	0	1	2017	2017	7.0	low	0	1	0
Innate Inflammatory Response	0	1	2017	2017	7.0	low	0	1	0
Kidney Neoplasms	0	1	2020	2020	4.0	low	0	1	0
Liver Neoplasms	0	1	2017	2017	7.0	low	0	1	0
Lung Adenocarcinoma	0	1	2018	2018	6.0	low	0	1	0
Lung Neoplasms	0	1	2018	2018	6.0	low	0	1	0
Lymphoma	0	1	2020	2020	4.0	low	0	1	0
Medulloblastoma	0	1	2015	2015	9.0	low	0	1	0
Milk-Alkali Syndrome	0	1	2023	2023	1.0	low	1	0	1
Myocardial Infarction	0	1	2017	2017	7.0	low	0	1	0
Neoplasms	0	8	2013	2022	5.6	low	1	4	4
Neoplasms, Germ Cell and Embryonal	0	1	2021	2021	3.0	low	0	0	1
Neuroblastoma	0	1	2015	2015	9.0	low	0	1	0
Papillomavirus Infections	0	1	2018	2018	6.0	low	0	1	0
Parkinson Disease	0	1	2018	2018	6.0	low	0	1	0
Peripheral Nerve Diseases	0	1	2019	2019	5.0	low	0	1	0
Peripheral Nervous System Diseases	0	1	2019	2019	5.0	low	0	1	0
Polycystic Kidney, Autosomal Dominant	0	1	2018	2018	6.0	low	0	1	0
Prostatic Neoplasms	0	1	2016	2016	8.0	low	0	1	0
Rhabdomyosarcoma, Embryonal	0	1	2020	2020	4.0	low	0	1	0
Sepsis	0	1	2021	2021	3.0	low	0	0	1
Skin Neoplasms	0	1	2018	2018	6.0	low	0	1	0
Squamous Cell Carcinoma of Head and Neck	0	1	2021	2021	3.0	low	0	0	1
Testicular Neoplasms	0	1	2021	2021	3.0	low	0	0	1
Tongue Neoplasms	0	1	2021	2021	3.0	low	0	0	1
Triple Negative Breast Neoplasms	0	1	2015	2015	9.0	low	0	1	0
Zika Virus Infection	0	1	2020	2020	4.0	low	0	1	0

Bioavailability (6)

Article	Year
Model-based dose selection to inform translational clinical oncology development of WNT974, a first-in-class Porcupine inhibitor. Clinical and translational science, , Volume: 15, Issue:7	2022
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, , Volume: 96, Issue:5	2019
Potent in vivo lung cancer Wnt signaling inhibition via cyclodextrin-LGK974 inclusion complexes. Journal of controlled release : official journal of the Controlled Release Society, , 11-28, Volume: 290	2018
Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors. ACS medicinal chemistry letters, , Jul-14, Volume: 7, Issue:7	2016
Design, synthesis, and evaluation of potent Wnt signaling inhibitors featuring a fused 3-ring system. European journal of medicinal chemistry, , Jan-27, Volume: 108	2016
The use of porcupine inhibitors to target Wnt-driven cancers. Bioorganic & medicinal chemistry letters, , Dec-01, Volume: 25, Issue:23	2015

Dosage (3)

Article	Year
A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer. The oncologist, , 03-17, Volume: 28, Issue:3	2023
Model-based dose selection to inform translational clinical oncology development of WNT974, a first-in-class Porcupine inhibitor. Clinical and translational science, , Volume: 15, Issue:7	2022
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. British journal of cancer, , Volume: 125, Issue:1	2021